AAAAAA

   
Results: 1-19 |
Results: 19
Pharmacokinetics of reboxetine in healthy volunteers with different ethnicdescents
Authors: Hendershot, PE Fleishaker, JC Lin, KM Nuccio, ID Poland, RE
Citation: Pe. Hendershot et al., Pharmacokinetics of reboxetine in healthy volunteers with different ethnicdescents, PSYCHOPHAR, 155(2), 2001, pp. 148-153
Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers
Authors: Fleishaker, JC Sisson, TA Carel, BJ Azie, NE
Citation: Jc. Fleishaker et al., Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers, CEPHALALGIA, 21(1), 2001, pp. 61-65
Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans
Authors: Fleishaker, JC Ryan, KK Jansat, JM Carel, BJ Bell, DJA Burke, MT Azie, NE
Citation: Jc. Fleishaker et al., Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans, BR J CL PH, 51(5), 2001, pp. 437-441
Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers
Authors: Fleishaker, JC Ryan, KK Carel, BJ Azie, NE
Citation: Jc. Fleishaker et al., Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers, J CLIN PHAR, 41(2), 2001, pp. 217-223
Lack of effect of reboxetine on cardiac repolarization
Authors: Fleishaker, JC Francom, SF Herman, BD Knuth, DW Azie, NE
Citation: Jc. Fleishaker et al., Lack of effect of reboxetine on cardiac repolarization, CLIN PHARM, 70(3), 2001, pp. 261-269
Pharmacokinetics of reboxetine in volunteers with hepatic impairment
Authors: Tran, A Laneury, JP Duchene, P Jannuzzo, MG Fleishaker, JC Houin, G Rampal, P
Citation: A. Tran et al., Pharmacokinetics of reboxetine in volunteers with hepatic impairment, CLIN DRUG I, 19(6), 2000, pp. 473-477
Pharmacokinetics and metabolism of reboxetine
Authors: Fleishaker, JC
Citation: Jc. Fleishaker, Pharmacokinetics and metabolism of reboxetine, REV CONT PH, 11(5), 2000, pp. 283-293
Pharmacokinetics of reboxetine in elderly patients with depressive disorders
Authors: Poggesi, I Pellizzoni, C Fleishaker, JC
Citation: I. Poggesi et al., Pharmacokinetics of reboxetine in elderly patients with depressive disorders, INT J CL PH, 38(5), 2000, pp. 254-259
Pharmacokinetics of reboxetine in healthy, elderly volunteers
Authors: Bergmann, JF Laneury, JP Duchene, P Fleishaker, JC Houin, G Segrestaa, JM
Citation: Jf. Bergmann et al., Pharmacokinetics of reboxetine in healthy, elderly volunteers, EUR J DRUG, 25(3-4), 2000, pp. 195-198
Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression
Authors: Fleishaker, JC
Citation: Jc. Fleishaker, Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression, CLIN PHARMA, 39(6), 2000, pp. 413-427
Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency
Authors: Coulomb, F Ducret, F Laneury, JP Fiorentini, F Poggesi, I Jannuzzo, MG Fleishaker, JC Houin, G Duchene, P
Citation: F. Coulomb et al., Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency, J CLIN PHAR, 40(5), 2000, pp. 482-487
Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers
Authors: Fleishaker, JC Sisson, TA Carel, BJ Azie, NE
Citation: Jc. Fleishaker et al., Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers, CLIN PHARM, 67(5), 2000, pp. 498-503
Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers
Authors: Fleishaker, JC Herman, BD Pearson, LK Ionita, A Mucci, M
Citation: Jc. Fleishaker et al., Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers, CLIN DRUG I, 18(2), 1999, pp. 141-150
Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F
Authors: Fleishaker, JC Pearson, LK Knuth, DW Gomez-Mancilla, B Francom, SF McIntosh, MJ Freestone, S Azie, NE
Citation: Jc. Fleishaker et al., Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F, INT J CL PH, 37(10), 1999, pp. 487-492
Population pharmacokinetics of tirilazad: Effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhage
Authors: Fleishaker, JC Fiedler-Kelly, J Grasela, TH
Citation: Jc. Fleishaker et al., Population pharmacokinetics of tirilazad: Effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhage, PHARM RES, 16(4), 1999, pp. 575-583
Absolute bioavailability of reboxetine enantiomers and effect of gender onpharmacokinetics
Authors: Fleishaker, JC Mucci, M Pellizzoni, C Poggesi, I
Citation: Jc. Fleishaker et al., Absolute bioavailability of reboxetine enantiomers and effect of gender onpharmacokinetics, BIOPHARM DR, 20(1), 1999, pp. 53-57
Hormonal effects on tirilazad clearance in women: Assessment of the role of CYP3A
Authors: Fleishaker, JC Pearson, LK Pearson, PG Wienkers, LC Hopkins, NK Peters, GR
Citation: Jc. Fleishaker et al., Hormonal effects on tirilazad clearance in women: Assessment of the role of CYP3A, J CLIN PHAR, 39(3), 1999, pp. 260-267
Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans
Authors: Herman, BD Fleishaker, JC Brown, MT
Citation: Bd. Herman et al., Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans, CLIN PHARM, 66(4), 1999, pp. 374-379
Kinetic characterization and identification of the enzymes responsible forthe hepatic biotransformation of adinazolam and N-desmethyladinazolam in man
Authors: Venkatakrishnan, K Von Moltke, LL Duan, SX Fleishaker, JC Shader, RI Greenblatt, DJ
Citation: K. Venkatakrishnan et al., Kinetic characterization and identification of the enzymes responsible forthe hepatic biotransformation of adinazolam and N-desmethyladinazolam in man, J PHARM PHA, 50(3), 1998, pp. 265-274
Risultati: 1-19 |